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Background: Signalling proteins often contain several well defined and conserved protein domains. Structural
analyses of such domains by nuclear magnetic spectroscopy or X-ray crystallography may greatly inform the
function of proteins. A limiting step is often the production of sufficient amounts of the recombinant protein.
However, there is no particular way to predict whether a protein will be soluble when expressed in E.coli. Here we
report our experience with expression of a Src homology 2 (SH2) domain.
Results: The SH2 domain of the SH2D2A protein (or T cell specific adapter protein, TSAd) forms insoluble
aggregates when expressed as various GST-fusion proteins in Escherichia coli (E. coli). Alteration of the flanking
sequences, or growth temperature influenced expression and solubility of TSAd-SH2, however overall yield of
soluble protein remained low. The algorithm TANGO, which predicts amyloid fibril formation in eukaryotic cells,
identified a hydrophobic sequence within the TSAd-SH2 domain with high propensity for beta-aggregation.
Mutation to the corresponding amino acids of the related HSH2- (or ALX) SH2 domain increased the yield of soluble
TSAd-SH2 domains. High beta-aggregation values predicted by TANGO correlated with low solubility of
recombinant SH2 domains as reported in the literature.
Conclusions: Solubility of recombinant proteins expressed in E.coli can be predicted by TANGO, an algorithm
developed to determine the aggregation propensity of peptides. Targeted mutations representing corresponding
amino acids in similar protein domains may increase solubility of recombinant proteins.
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Protein solubilityBackground
Src homology 2 (SH2) are structurally conserved protein
domains of approximately100 amino acids (aa). SH2 do-
mains regulate numerous intracellular signal transduction
events through interaction with tyrosine phosphorylated
proteins [1]. Within the human genome, 110 distinct genes
encode for 120 SH2 domains [2]. SH2 domains consist
of an N-terminal alpha helix (αA) flanking a central
five-stranded anti-parallel beta sheet (βB-F) followed
by a second alpha helix (αB) and a C-terminal beta strand* Correspondence: anne.spurkland@medisin.uio.no
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reproduction in any medium, provided the or[3] (Figure 1). The five strands of the central beta sheet
separate a conserved phosphotyrosine binding pocket
from a more variable pocket that typically binds the third
amino acid C-terminal to the phosphorylated tyrosine.
Detailed structural analyses have revealed specific and
unique features of different SH2 domains suggesting that
these domains, while ubiquitous and highly conserved,
nevertheless exhibit unique specificity determining fea-
tures. For example, NMR analysis of the SH2 domain of
Inducible Tec Kinase (Itk) showed that its binding speci-
ficity is modulated by cis-trans isomerization of a single
proline [4]. Structural analysis of the SH2D1A gene prod-
uct, Slam associated protein (SAP), revealed the structural
basis for a phosphotyrosine independent three-prongedral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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SH2D2A   homo    95  WFHGFITRREAERLLEPKPQ  GCYLVRFSESAV TFVLTYRSRT     CCRHFLLAQL 
SH2D2A   mouse    116  ---------------Q-Q-L  ------------ ----S---Q-     ---------- 
SH2D2A   rat    116  ---------------QSQ-L  ------------ ----S-----     ---------- 
HSH2     homo   33  ----A-S-ED--N---SQ-L  -SF-I-V-H-H- GYT-S-KAQS     S-C--MVKL- 
Lck      homo   126  --FKNLS-KD--RQ-LAPGNTH-SF-I-E---TAGS-S-SV-DFDQNQGEVVK-YKIRN- 
SH2D2A   homo           RDGRHVVLGEDSAHARLQDLLLHYTAHPLSPYGETLTEPLAR    QTPEPAGLSLR 200 
SH2D2A   mouse       G-------------- Q-----E---EC------I--R----    ---A------- 221 
SH2D2A   rar           G-------------- Q-----Q---EC------M--R----    ---A------- 221 
H2H2D    homo           D--TFMIP--KV--TS-DA-VTFHQQK-IE-RR-L--Q-CRQ    KD-ANVDYEDL 138 
Lck      homo           DN-GFYI SPRITFP G-HE-VR---NASDGLCTR-SR-CQT    -K-QKPWWEDE 237 
Figure 1 Alignment of SH2 domains. Alpha helices are indicated by open ovals and beta sheets are indicated by open arrows. “-“: position is
identical to human SH2D2A sequence. “ “: gap in the alignment. Nomenclature for SH2 domain segments from [3].
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Similarly, a disulphide bond in the SH2 domain of the
C-terminal Src kinase (Csk) was found to be central
for the kinase activity [6].
The function and specificity determining elements of
many SH2 domain containing proteins, are still not
well characterised. One of these is the T cell specific
adapter protein (TSAd), encoded by the SH2D2A gene
and expressed in activated T cells [7] and endothelial
cells [8]. TSAd contains one SH2 domain, followed by
a proline rich region and possesses ligands for SH2 and
SH3 domains [9]. Hitherto only a few ligands for the
human TSAd SH2 domain are known, including the
phosphorylated vascular endothelial growth factor receptor
2 (VEGFR-2) [8,10], and the phosphorylated valocin con-
taining protein (VCP) [11]. Recruitment of TSAd via SH2
domain binding to phosphorylated Y951 in the VEGFR2 re-
ceptor controls migration of [8] as well as permeability [12]
of endothelial cells. Similarly, binding of TSAd via its SH2
domain to VCP is required for nuclear translocation of
TSAd [11]. Preliminary results from our lab indicate that
the TSAd-SH2 domain has additional ligands in activated
T cells (Hem, unpublished observations). Given the inter-
esting biology surrounding TSAd, and the role of SH2 do-
mains in mediating important interactions in the context
of cell signalling, we wanted to characterize the structure
of TSAd SH2. However, when expressed as a GST-fusion
protein in E. coli, the TSAd SH2 domain was found to
be highly insoluble presenting a significant challenge
to detailed structural characterization.
An algorithm for prediction of amyloid fibril formation
in eukaryote cells, TANGO, has been developed [13], and it
has been suggested that TANGO may also predict inclusion
body formation in prokaryotic cells [14]. Here we report
that TANGO predicts the solubility of recombinant SH2
domains expressed in E.coli, and that predictions made byTANGO allowed for targeted mutations that significantly
improved the solubility of the recombinant protein.
Results
Low solubility of bacterially expressed human TSAd
SH2 domain
To perform biochemical and structural studies on the
TSAd SH2 domain, we initially generated a GST-fusion
construct (1-TD, Figure 2A) including the flanking amino
acids 67–94 and 189–207. The resulting GST-TSAd SH2
domain was expressed mainly as insoluble inclusion bodies
(compare lane 1 and 2, Figure 2B). In contrast, the GST-
Lck SH2 protein containing only minimal gene-derived
flanking sequence was primarily expressed in the soluble
fraction (compare lane 4 and 5, Figure 2B). Although small
amounts of recombinant GST-TSAd SH2 was present in
the lysate, most of this soluble fraction could be captured
on glutathione sepharose beads (lane 3, Figure 2B).
Anti-GST-immunoblotting of equal amounts of the soluble
fractions compared to a defined amount of purified, soluble
GST (Figure 2C,i), revealed that the yield of the TSAd SH2
domain) was only 0,15 mg/l bacterial cell culture, while that
of Lck-SH2 was estimated to be close to 20 mg/l bacterial
culture (Figure 2D).
Flanking sequences, growth temperature and genetic
variation influence recombinant expression of TSAd
SH2 domains
Having found that the protein yield of the TSAd-SH2
domain construct was only a fraction of that of the
Lck-SH2 construct, additional constructs including dif-
ferent lengths of the sequence flanking the human
TSAd SH2 domain and three different vector-encoded
C-termini (Figure 2A and Table 1) were generated. When
expressed at room temperature, the yield of these TSAd
SH2 domain constructs varied considerably as judged by
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Figure 2 Expression and solubility of GST-TSAd SH2 domains are
influenced by flanking sequence and growth temperature. A.
Schematic overview of the GST-fusion SH2 constructs (given in Table 1)
used in this study. B. GST-fusion SH2 constructs of TSAd (1-TD,
TSAd-67-207-IVTD) and Lck (Lck-SH2, Lck-124-228-RPHRD) were
expressed in E.coli at room temperature (RT). Equal volumes of
resuspended pellet (P), soluble fraction (S) and glutathione beads
(B) were separated by 10% SDS-PAGE. Proteins were visualised by
Coomassie Brilliant Blue staining. C. Quantitation of the amount of
soluble GST-SH2 proteins shown in B, by immunoblotting with
anti-GST and comparison to defined amounts of GST. 5 μl of 2 ml
TSAd-SH2 soluble fraction and 0,06 μl of 2 ml Lck-SH2 soluble fraction
from 100 ml bacterial cultures were applied on the gel. GST = 1
represents a total amount of 0,11 μg GST applied on the gel. D.
Quantitation of soluble GST-SH2 proteins using Image J analysis based
on C. E and F. Yield of expression of the six GST-TSAd SH2 domain
constructs in E.coli at RT or 15°C, respectively. Gels processed as in B.
Constructs are indicated by their short names as listed in Table 1.
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67-207-IVTD construct (1-TD), truncation of the sequence
N- and/or C-terminal to the TSAd SH2 domain yielded
approximately equal levels of expressed protein (Figure 2E,
lanes 2, 4, 6 and 12). By contrast the TSAd-90-188-PHRD
(5-RD) construct was not expressed at all (Figure 2E, lane 9
and 10). This construct only differed from TSAd-90-188-
PAAS (5-AS) in its C-terminal vector-derived sequence,
and from TSAd-67-188-PHRD (3-RD) in that the latter
includes 37 aa N- terminal to the SH2 domain (Table 1).
Growth temperature affects the solubility of recombinant
proteins in E.coli [15]. Expression at 15°C resulted in higher
yield of soluble TSAd SH2 domain from the TSAd-67-207-
IVTD (1-TD), TSAd-90-207-IVTD (2-TD), TSAd-81-193-
PAAS (4-AS) and TSAd-90-188-PAAS (5-AS) constructs,
whereas solubility and expression of the TSAd-67-188-
PHRD (5-RD) and TSAd-90-188-PHRD (3-RD) constructs
remained unchanged (Figure 2F). We also tested whether
the genetic variation inherent in species differences
(Figure 1) affected expression of TSAd SH2 domains.
Analysis of solubility and yield of identically cloned
TSAd SH2 domains derived from three different species
(constructs TSAd-90-188-PAAS (5-AS), mTSAd-111-210-
AAAS (mTSAd) and rTSAd-111-210-AAAS (rTSAd),
Table 1) revealed slightly improved solubility at 15°C
of murine TSAd SH2 compared to human and rat (data
not shown). Taken together, both gene- and vector-derived
sequence influence the overall expression and solubility of
recombinant TSAd-SH2 proteins. However, none of the
conditions tested resulted in amounts of soluble recombin-
ant TSAd SH2 domain sufficient for structural analysis.
The TSAd SH2 domain contains a short peptide sequence
promoting intermolecular beta-sheet aggregation
In order to examine whether the TSAd SH2 domain has
some intrinsic property limiting its solubility in prokaryotic
cells [14], we took advantage of an algorithm for prediction
Table 1 Overview of SH2 domain constructs included in this study
Short name Construct Gene Accession number Species Start aa End aa C-terminal vector
derived sequence
Construct total
length (aa)
1-TD TSAd-67-207-IVTD SH2D2A NP_003966 H sapiens S67 S207 IVTD 145
2-TD TSAd-90-207-IVTD SH2D2A NP_003966 H sapiens G90 S207 IVTD 122
3-RD TSAd-67-188-PHRD SH2D2A NP_003966 H sapiens S67 R188 PHRD 126
4-AS TSAd-81-193-PAAS SH2D2A NP_003966 H sapiens T81 P193 PAAS 117
5-RD TSAd-90-188-PHRD SH2D2A NP_003966 H sapiens G90 R188 PHRD 103
5-AS TSAd-90-188-PAAS SH2D2A NP_003966 H sapiens G90 R188 PAAS 103
mTSAd mTSAd-111-210-AAAS SH2D2A NP_001020742 M musculus K111 R210 AAAS 104
rTSAd rTSAd-111-209-AAAS SH2D2A NP_997488 R norvegicus R111 R209 AAAS 103
ALX ALX-31-126-RPHRD HSH2 NP_116244 H sapiens G30 R126 RPHRD 101
Lck Lck-124-228-RPHRD Lck NP_005347 H sapiens P124 K228 RPHRD 110
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(http://tango.crg.es). TANGO analysis of the human TSAd
SH2 domain sequence (S90-R188) revealed that the
βC strand of the human TSAd SH2 domain (Figure 1)
harbours a nine aa sequence (SAVTFVLTY) with near
100% propensity for intermolecular beta-sheet aggrega-
tion (Figure 3A). Similar results were obtained for the
murine and rat sequences, whereas no beta-aggregating
regions were found in the Lck-SH2 domain, nor in the
TSAd homologue ALX SH2 [2,16] (data not shown, and
Figure 3A, upper right panel). In silico substitution of
the TSAd sequence AVTFVLT to the corresponding ALX
sequence HVGYTLS and vice versa, reduced the predicted
beta-aggregation propensity of the TSAd SH2 domain
to near zero, whereas the ALX SH2 domain attained
beta-aggregation propensity similar to that of the native
TSAd SH2 domain (Figure 3A, bottom panels). Further
in silico replacements revealed that exchange of the TFV
sequence in TSAd to the GYT sequence of ALX, resulted
in a 90% reduction in the overall beta-aggregation propen-
sity of TSAd SH2 (Figure 3B). As the structure of the
TSAd-SH2 domain is not yet determined, we instead
compared the structures of the Lck-SH2 domain and
the ALX-SH2 domain to visualize the putative localisa-
tion of the TFV sequence in the SH2 domain structure
(Figure 3C). The tripeptide region corresponding to the
TSAd-SH2 TFV sequence (SFS and GYT respectively) is
highlighted. As can be seen from the space filling models
the Ser 161 and Ser 163 in Lck, and all three amino acids
in the ALX-motif (Gly65, Tyr66 and Thr67), are solvent
accessible. Given the structural conservation between SH2
domain folds, it is likely that at least part of the TFV
sequence in TSAd-SH2 may be solvent exposed. When
the TFV sequence from TSAd-SH2 was in silico re-
placed with the GYT sequence in the ALX-SH2 domain
sequence, the TANGO algorithm predicted an increase
in beta-aggregation propensity corresponding to the TFV
sequence (Table 2). To directly test the predictions madeby TANGO, we generated TFV→GYT and FV→YT mu-
tants of the TSAd-90-188-PHRD and TSAd-90-188-PAAS
constructs, and compared their expression to that of the
ALX SH2 domain. These constructs were chosen, as they
contained the shortest flanking sequences compared to the
original TSAd 1-TD construct, and were thus better suited
for the planned down stream analysis. The TFV→GYT
mutation increased both yield and solubility of the TSAd
SH2 domains (Additional file 1: Figure S1), most dramatic-
ally for the TSAd-90-188-PHRD construct, which was not
expressed as soluble protein in its wild type form (Figure 2E
and Figure 3D-F). As predicted by TANGO (Figure 3B and
Table 2), the FV→YT replacement influenced solubility of
the TSAd SH2 domain produced by TSAd-90-188-PAAS
to a lesser extent, and had no effect in the TSAd-90-188-
PHRD construct (Figure 3D-F). Compared to the original
TSAd-SH2 construct (1-TD) which consistently yielded
0,15 mg/l bacterial culture (Figure 2D and 3E), the yield of
soluble wild type TSAd-90-188-PAAS protein was doubled,
and was further increased by 50% when mutated to GYT
(Figure 3D), yielding close to 0,5 mg recombinant protein
per liter bacterial cell culture. For the TSAd-90-188-PHRD
protein mutated to GYT, the yield of soluble protein
was doubled (i.e. 0,3 mg/l bacterial culture) compared
to the original 1-TD construct (Figure 3D). When the
reverse experiment was performed, replacing GYT se-
quence in the ALX SH2 domain with TFV, no adverse
effect on solubility was observed (Figure 3G). An over-
view of the TANGO-predicted aggregation scores and
yield of soluble protein for the various SH2 domains
included in this study are given in Table 2. Thus, taken
together TANGO predictions allowed for targeted muta-
tions resulting in increased solubility of the TSAd SH2 do-
main in prokaryotic cells. However, the insertion of the
TFV sequence alone into the ALX-SH2 domain was not
enough to render this protein insoluble, indicating that
TANGO will not always be able to predict solubility of
recombinant proteins in E.coli.
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Figure 3 Beta-aggregation prediction of the SH2D2A SH2 domain. A. Amino acid positions of the indicated SH2 domains (X-axis) plotted
against the corresponding beta-aggregating value (Y-axis). B. Beta-aggregation values of amino acids 122–135 in wild type (WT) and in silico
mutated SH2D2A encoding TSAd. C. Ribbon diagrams and space filling models of the Lck SH2 domain (PDB ID: 1BHH) and the ALX SH2 domain
(PDB ID: 2CS0) showing the location of Ser-Phe-Ser (Lck) and Gly-Tyr-Thr (ALX) corresponding to the TSAd TFV sequence. Models show that the
side chains of Ser 161 and Ser 163 in Lck SH2 and Gly65, Tyr66 and Thr67 of ALX SH2 are solvent accessible. D.-F. WT and mutated SH2
domains expressed in E.coli at 15°C. D. Equal amount (5 μl) of soluble fraction from a 100 ml bacterial culture was separated by SDS-page and
immunoblotted with anti-GST antibodies for quantification of soluble recombinant protein. GST = 1 equals 0,11 μg purified GST protein. One
representative experiment out of three is shown. E. Quantitation of soluble GST-SH2 proteins by Image J analysis based on D. ND; not detected.
F. Soluble protein captured on glutathione beads were processed as in Fig. 2B. G. Solubility of WT and mutated TSAd SH2 (5-AS, TSAd-90-188-PAAS)
(GYT) and ALX SH2 (TFV) expressed in E.coli. Uninduced E.coli (U), soluble (S) and pellet (P) fractions were processed as in Fig. 2B. Amount of soluble
and insoluble SH2 domain visualized by anti-GST immunoblotting (upper panel). Total protein content in samples was visualized by Coomassie Brilliant
Blue Staining (lower panel). H. CD3 stimulated Jurkat cell lysates (S) and proteins pulled down with the indicated SH2 domains were separated by
SDS-page and immunoblotted. I. Peptide array with VEGFR-2 and VCP phosphotyrosine peptides probed with the indicated SH2 domains. Bound SH2
domains detected using anti-GST antibody.
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Table 2 Overview of predicted TANGO aggregation score, production yield and pull-down activity for SH2 domain
constructs included in this study
Short name Construct TANGO predicted
aggregation score
Production yield
(mg/L bacterial culture)
pY-protein binding
activity (pull-down)
1-TD TSAd-67-207-IVTD 793 0,15 ND
2-TD TSAd-90-207-IVTD 774 ND ND
3-RD TSAd-67-188-PHRD 791 ND ND
4-AS TSAd-81-193-PAAS 771 ND ND
5-RD TSAd-90-188-PHRD 773 ─ ND
5-RD YT TSAd-90-188-PHRD 342 ─ ND
5-RD GYT TSAd-90-188-PHRD 103 0,35 ND
5-AS TSAd-90-188-PHRD 772 0,37 +++
5-AS YT TSAd-90-188-PAAS 339 0,42 ND
5-AS GYT TSAd-90-188-PAAS 102 0,48 ++
mTSAd mTSAd-111-210-AAAS 745 ND ND
rTSAd rTSAd-111-209-AAAS 744 ND +++*
ALX ALX-31-126-RPHRD 63 ND ND
ALX TFV ALX-31-126-RPHRD 488 ND ND
Lck Lck-124-228-RPHRD 24 19,46 +++*
ND, not determined; ─, below detection limit; +++, strong signal; ++, signal.
*, data not shown.
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phosphorylated proteins
Pull-down assays were performed to test whether the tar-
geted mutations negatively influenced the function of the
TSAd SH2 domain. Tyrosine phosphorylation of cellular
proteins was induced in Jurkat T cells by anti-CD3 trig-
gering. Lysates from stimulated cells were subjected to
pull-down assay, using wild type and GYT-mutated
GST-TSAd SH2 (TSAd-90-188-PAAS). Both constructs
pulled down the same tyrosine phosphorylated proteins,
although smaller amounts were pulled down using the
GYT- mutated protein. However, some protein bands
seemed to be more affected by the GYT mutation than
others (Figure 3H). To further analyze the binding specifi-
city of the mutated TSAd SH2 domain, peptide arrays
representing phosphopeptides from VEGFR-2 and VCP, the
two known TSAd SH2 domain ligands, were probed with
wild type or mutated TSAd SH2 (TSAd-90-188-PAAS)
domain. The results show that both TSAd wild type and
GYT-mutated protein bind to VEGFR-2 phosphopeptide
(pY951) and VCP (pY805), whereas binding to VCP pY796
was lost for the GYT-mutant (Figure 3I). The GYT→TFV
replacement in ALX SH2 domain did not alter the speci-
ficity towards the selected phosphopeptides (Figure 3I).
Taken together, the results show that although the mutant
protein may have retained all or most of the assessed
functions of the wild type protein, the specificity deter-
mining elements of the mutated protein domain may
be altered. This should be carefully addressed whenmutations are introduced for the purpose of increasing
the solubility of the expressed protein.
Low beta-aggregation values predict high solubility of
recombinant SH2 domains
Having found that TANGO could predict increased solu-
bility of the TSAd-SH2 domain, we then asked whether
beta-aggregation propensity is a common characteristic
of SH2 domains. Most of the 120 SH2 domains encoded
by the human genome have been expressed as recombinant
His- [17] or GST-fusion proteins [18,19]. All available hu-
man SH2 domain sequences [2] were analysed by TANGO
(Additional file 2: Table S1) and results were correlated to
the recently published information on SH2 solubility. SH2
domains displaying low solubility had significantly higher
beta-aggregation values than SH2 domains which were
soluble [18] (Figure 4A) and [19] (data not shown).
Similarly, the percentage of recombinant SH2 domains
present as monomers (an indicator of protein solubility)
as evaluated by analytical size exclusion chromatography
[17], was inversely correlated with high beta-aggregation
values (Figure 4B).
Discussion
Expression of recombinant proteins is an important step
forward for structural and functional analysis of entire
proteins and isolated protein domains. The choice of
tag may affect the solubility of the protein [20] and various
parameters for successful expression of heterologous
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Figure 4 Solubility of SH2 domains can be predicted by TANGO. A. Median beta aggregation values (Y axis) of SH2 domains grouped
according to solubility as reported by [19] (Mann-Whithney test p = 0.0002) B. Median beta aggregation values (+ SD) of SH2 domains plotted
against corresponding reported fraction of monomers (%) [17]. Line is fitted with linear regression, using GraphPad Prism (R2 = 0.19, p < 0.0001).
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[15,21]. However, there is no particular way to predict
whether a protein will be soluble when expressed in E.coli.
Having an interest in elucidating the function of the SH2
domain containing protein TSAd, we discovered that
its SH2 domain was mainly insoluble when expressed
in E.coli, as was also noted by others [17,18] but not all
[19]. Although alteration in flanking sequence and growth
temperature influenced expression and solubility of TSAd
SH2, overall yield of soluble protein remained low.
Protein aggregation and amyloid fibril formation in de-
generative diseases such as Alzheimer’s disease resembles
the process of inclusion body formation in E.coli [14]. To
our knowledge targeted mutation to relieve propensity for
intermolecular beta-aggregation and increase solubility of
recombinant proteins has not previously been reported,
although the opposite experiment has been performed: de
Groot and Ventura fused green fluorescent protein (GFP)
to a mutated Aβ42 Alzheimer peptide to generate an ag-
gregation prone reporter for monitoring protein quality in
inclusion bodies by measuring GFP emission spectra [22].
Our results show that identification of aggregation prone
proteins in silico allow for targeted mutations to increase
solubility of the recombinant protein. Provided the overall
structure and function of the recombinant protein are
retained, this is a potentially efficient strategy to generate
soluble recombinant protein for downstream purposes.
Aggregating peptide sequences are common within the
hydrophobic core of globular proteins [23]. Accordingly,
the beta-aggregating sequence identified by TANGO in the
TSAd-SH2 domain (and also in many of the other SH2 do-
mains with high beta-aggregating propensity (not shown))
was found in βC located in the core of the SH2 domain.
Histidines, arginines or prolines are preferred immediatelyprior to, and after, aggregating sequences in the prote-
ome. These gatekeeper amino acids may counteract
beta-aggregating propensity, and may also serve as rec-
ognition sites for chaperones [24]. Although SH2 do-
mains share overall structure, there is large sequence
variability between individual domains of the family
[2]. Interestingly, although most SH2 domains did not
harbour aggregating βC sequences, the large majority
still had histidine, arginine or proline flanking the βC
sequence on each side (see alignment in [2]). This suggests
that protein domain families may have evolved to resist
the potential deleterious effects of beta-aggregating
propensity of globular proteins.
Conclusions
We have found that TANGO, an algorithm developed to
predict amyloid fibril formation and aggregation of pep-
tides, may also predict the solubility of recombinant SH2
domains expressed in E.coli. Predictions made by TANGO
may allow for targeted mutations that significantly im-
prove the solubility of the recombinant protein. Mutations
introduced for the purpose of increasing the solubility
of the expressed protein may alter specificity determin-
ing elements of the mutated protein domain.
Methods
Plasmid constructs
TSAd SH2, Lck SH2 and ALX SH2 encoding DNA were
isolated from intact cDNA clones [9,16,25] by in vitro
amplification, and cloned into the BamHI/NotI or EcoR/
NotI site of the bacterial expression vector pGEX-6P-1
(GE Healthcare). The aa sequence alignment of the
TSAd SH2 domains encoded by human, mouse and rat
SH2D2A genes as well as the human Lck SH2 and ALX
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includes the predicted secondary structures of these SH2
domains with nomenclature as defined in [3].The different
constructs made are shown in Table 1 and are schematic-
ally represented in Figure 2A. Mutagenesis was performed
using Quickchange (Clontech). All constructs were verified
by sequencing.
Protein expression
Glutathion S-transferase (GST) SH2 domain fusion
proteins were made by isolating single clones of E.coli
BL21-CodonPlus-RP (Stratagene,) transformed with
appropriate cDNA constructs. Colonies were grown in
LB medium at 37°C or in M9 minimal salt medium at
25°C to OD600 = 0.6-0.8, prior to addition of isopropyl-
beta-D-thiogalactoside (IPTG) (Sigma-Aldrich) to a
final concentration of 0.2 mM followed by incubation
at room temperature or 15°C for 4–16 hours. Cultures
were harvested by centrifugation, lysed in PBS with
0,5 mg/ml lysozyme followed by one freeze-thaw cycle
(−80°C over night) and further lysis in GST-lysis buffer
(1% Triton X-100, 1 mM DTT, 1 mM PMSF, 0,5 mg/ml
lysozyme, 5 μg/ml DNAse, PBS pH 7.4) for ~16 h at
4˚C with agitation. Following centrifugation, soluble and
insoluble (pellet) fractions were separated. The pellet was
resuspended in an equal volume of PBS pH 7.4. Soluble
and pellet fractions were analysed by SDS-PAGE followed
by Coomassie Brilliant Blue staining or by western blotting
using antibodies specific for GST (clone B14) (Santa Cruz
Biotechnology, Santa Cruz, CA). Signals were developed
using horse peroxidase-conjugated goat anti-mouse IgG
(Jackson ImmunoResearch Laboratories, West Grove, PA)
followed by Super Signal® west Pico Stable Peroxide
Solution (Pierce, Rockford, IL).
Protein purification
Protein was purified in bulk from lysates using
Glutathione-Sepharose 4B beads (GE Healthcare) as
described by the manufacturer. Beads were stored at 4°C in
PBS pH 7.4. Expression level and purity of protein was ex-
amined by SDS-PAGE. Protein bands were directly visua-
lised by staining of the gel with Coomassie Brilliant Blue.
Antibodies, cell stimulation, and pulldown experiments
The following mAb were used; anti-human CD3ε (OKT3,
American Type Culture collection, Manassas, VA), anti-
GST (B-14,Santa Cruz Biotechnology, Santa Cruz, CA),
anti-phosphotyrosine (anti-pY) (clone 4G10, Upstate Bio-
technology, Lake Placid, NY), and horseradish peroxidase-
conjugated goat-anti mouse IgG mAb (Sigma-Aldrich).
Pull-down experiments using anti-CD3 stimulated Jurkat
E6.1 cells (American Type Culture Collection) and GST-
TSAd SH2 fusion proteins on glutathione sepharose beads
were performed as previously described [9].Semi quantitative assessment of GST-fusion proteins
For semi-quantitative assessment of soluble GST-fusion
proteins in bacterial lysate, GST was expressed from
expression vectors without insert, purified in bulk as
described above and then eluted from glutathione beads
using glutathione as described by the manufacturer. The
eluted protein was quantified using NanoDrop 2000c
spectrophotometry (Thermo scientific, Wilmington, DE). A
standard curve of 3 fold dilutions of the GST protein was
included on the SDS-PAGE and the immunoblot signals
from anti-GST (clone B14) (Santa Cruz Biotechnology,
Santa Cruz, CA) were visually compared. Additionally, the
amount of soluble protein was assessed by signal intensity
meassurements using the image processing ImageJ software
(http://rsb.info.nih.gov/ij/index.html). At least two inde-
pendent membranes were examined for each quantitation.
Peptide spot array analysis
Peptide arrays were synthesized on nitrocellulose mem-
branes using a MultiPep automated peptide synthesizer
(INTAVIS Bioanalytical Instruments AG, Germany) as
described [26,27]. Membranes were probed with GST-
tagged SH2 fusion proteins (80 μg/ml), and signals
were detected using relevant antibodies followed by
chemiluminescent detection.
Prediction of protein aggregation
Prediction of aggregating regions of unfolded polypep-
tide chains were performed using the algorithm TANGO
(http://tango.crg.es), using the default conditions pH 7.0,
25°C and 0.02 mM ionic strength [13,23,28].
Additional files
Additional file 1: Figure S1. Yield and solubility of mutated TSAd-SH2
domains. WT and mutated SH2 domains as indicated were expressed in
E.coli at 15°C. Soluble and pellet fractions were separated by 10%
SDS-PAGE. Proteins were visualised by Coomassie Brilliant Blue staining.
Additional file 2: Table S1. SH2 domains analysed by TANGO.
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